Your search for bevacizumab returned 6 results

Alymsys is a vascular endothelial growth factor inhibitor.

Vegzelma is a vascular endothelial growth factor inhibitor.

At the end of one year, likelihood of being weaned off treatment was higher for eyes treated with aflibercept versus bevacizumab

The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of October. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…

The approval was based on data from the SORAYA trial.